Novavax (NVAX) | Stock Overview & Key Data
Novavax Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $331.68 on February 8, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Novavax NVAX | 1.02B Small-cap | 4.92% | -10.80% | 1.07% | -38.91% | -22.87% | -42.86% | -91.07% | -92.79% |
| Vertex VRTX | 114.06B Large-cap | 3.19% | 2.97% | -3.19% | 12.51% | 13.22% | -3.15% | 56.18% | 56.09% |
| Regeneron REGN | 55.27B Large-cap | 2.50% | 3.96% | -6.05% | -26.32% | -24.76% | -47.08% | -11.94% | -11.84% |
| Vera Therapeutics VERA | 1.38B Small-cap | -2.50% | 3.52% | 15.20% | -45.44% | -45.57% | -32.64% | 63.38% | 108.70% |
| Immunocore Holdings IMCR | 1.56B Small-cap | 3.28% | -10.15% | 23.33% | 5.16% | 8.69% | -10.68% | -26.05% | -23.56% |
| Agios AGIO | 1.93B Small-cap | 5.86% | 4.60% | 35.95% | 0.26% | 10.58% | -15.43% | 38.73% | -31.81% |
Ownership & Short Interest
Novavax Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Novavax would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
In the last 52 weeks, Novavax reached a high of $17.81 (on July 26, 2024) and a low of $5.01 (on April 10, 2025).
Curious about Novavax's size and valuation? Its market capitalization stands at 1.02B. When it comes to valuation, the P/E ratio (trailing twelve months) is 2.29, and the forward P/E (looking ahead) is -39.44.
As for dividends, Novavax isn't currently offering a significant yield, or that specific data isn't available right now.
When looking at Novavax, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX114.06B Healthcare Biotechnology -3.15% 56.18% Regeneron
REGN55.27B Healthcare Biotechnology -47.08% -11.94% Vera Therapeutics
VERA1.38B Healthcare Biotechnology -32.64% 63.38% Immunocore Holdings
IMCR1.56B Healthcare Biotechnology -10.68% -26.05% Agios
AGIO1.93B Healthcare Biotechnology -15.43% 38.73% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
To get a sense of Novavax's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 30.06%, the Debt to Equity ratio from the most recent quarter is -3.02, and its Gross Profit Margin stands at 97.75%.
Looking at Novavax's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 610.30%, and quarterly earnings saw a YoY growth of 567.34%.
Wondering who owns Novavax stock? Company insiders (like executives and directors) hold about 8.78% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 57.29%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.